Iterum Therapeutics (ITRM)
(Delayed Data from NSDQ)
$1.22 USD
+0.01 (0.83%)
Updated Jun 26, 2024 04:00 PM ET
After-Market: $1.22 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Income Statements
Fiscal Year end for Iterum Therapeutics PLC falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 47 | 30 | 25 | 32 | 102 |
Income After Depreciation & Amortization | -47 | -30 | -25 | -32 | -102 |
Non-Operating Income | 11 | -11 | -61 | -4 | -1 |
Interest Expense | 1 | 2 | 6 | 15 | 0 |
Pretax Income | -38 | -44 | -91 | -51 | -103 |
Income Taxes | 1 | 0 | 1 | 1 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -38 | -44 | -92 | -52 | -103 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -38 | -44 | -92 | -52 | -103 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -43 | -26 | -18 | -21 | -102 |
Depreciation & Amortization (Cash Flow) | 4 | 4 | 6 | 11 | 1 |
Income After Depreciation & Amortization | -47 | -30 | -25 | -32 | -102 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 12.96 | 12.24 | 10.90 | 1.60 | 0.97 |
Diluted EPS Before Non-Recurring Items | -2.96 | -3.63 | -2.10 | -20.99 | -106.45 |
Diluted Net EPS (GAAP) | -2.96 | -3.63 | -8.40 | -32.53 | -106.45 |
Fiscal Year end for Iterum Therapeutics PLC falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 6.17 | 11.43 | 16.68 | 10.82 | 8.53 |
Income After SG&A, R&D, and Dept/Amort Expenses | -6.17 | -11.43 | -16.68 | -10.82 | -8.53 |
Non-Operating Income | -0.40 | -0.38 | 13.27 | -0.91 | -0.84 |
Interest Expense | 0.49 | 0.41 | 0.30 | 0.32 | 0.40 |
Pretax Income | -7.05 | -12.22 | -3.72 | -12.06 | -9.77 |
Income Taxes | 0.05 | 0.14 | 0.16 | 0.19 | 0.12 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -7.10 | -12.36 | -3.88 | -12.24 | -9.89 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -7.10 | -12.36 | -3.88 | -12.24 | -9.89 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 15.43 | 13.18 | 13.04 | 12.94 | 12.68 |
Diluted EPS Before Non-Recurring Items | -0.46 | -0.94 | -0.30 | -0.95 | -0.78 |
Diluted Net EPS (GAAP) | -0.46 | -0.93 | -0.30 | -0.95 | -0.78 |